CD109 and cancer: We believe that our two novel anti-CD109 mAbs, which are directed against two distinct epitopes on the extracellular domain of CD109, are ideal tools for conducting detailed studies of the biological significance and diagnostic, prognostic and predictive values of CD109 in human cancers.